In the January–March 2015 edition of Corporate Disputes, Group Vice President and Global Practice Leader Dr. Gregory K. Bell and other industry experts discuss managing product liability in the pharma and healthcare sector. To read the article, click the link below.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.